Immunitybio

Immunitybio Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Immunitybio (IBRX) as of Oct 8, 2026 is -0.79. In the previous year, Net Debt to Free Cash Flow Ratio was -1.50 — a change of -47.46% (higher).

Net Debt/FCF

-0.79

YoY

-47.46%

Last updated:

Net Debt to Free Cash Flow Ratio of Immunitybio is 2025 -0.79 . Net Debt to Free Cash Flow Ratio of Immunitybio was 2024 -1.50 . It decreases by -47.46% higher compared to the previous year.

The Immunitybio Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
0.88 USD
Jan 1, 2019
0.33 USD
Jan 1, 2020
-1.01 USD
Jan 1, 2021
-0.94 USD
Jan 1, 2022
-1.37 USD
Jan 1, 2023
-1.44 USD
Jan 1, 2024
-1.50 USD
Jan 1, 2025
-0.79 USD
The Immunitybio Net Debt/FCF history
YEARNet Debt/FCFYoY
-0.79-47.46%
-1.50+4.30%
-1.44+5.43%
-1.37+45.76%
-0.94-6.95%
-1.01-409.58%
0.33-63.02%
0.88-41.74%
1.51-65.40%
4.36-59.17%
10.68+2.16%
10.46—
Access this data via the Eulerpool API

Immunitybio Stock analysis

What does Immunitybio do? Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immunitybio stock

Net Debt to Free Cash Flow Ratio of Immunitybio is -0.79 in 2025.

Net Debt to Free Cash Flow Ratio of Immunitybio changed from -1.50 to -0.79, representing a -47.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Immunitybio since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Immunitybio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Immunitybio

All Key Metrics — Immunitybio